Volume 15 Supplement 1
The value of the FDG-GaTate and proliferation marker (ki-67) in the assessment of neuroendocrine tumours (NETs)
© Fikri et al. 2015
Published: 2 October 2015
A combined tracer evaluation of Ga-68 DOTATATE (GaTate) and F-18 FDG (FDG) positron emission tomography (PET-CT) and the ki-67 marker have potential advantages over a single marker in determining the differentiation of NETs. This study is sought to evaluate their association and the potential role as predictive markers for the management impact.
Twenty-one combined FDG-GaTate studies were performed in various NETs lineages. A retrospective blinded review was performed based on the grade of tumour differentiation of ki-67 (European NET Society-ENETS) and the correlated Krenning scales (Grade 1-4) of the FDG-GaTATE PET-CT images. Subsequent management impact (high and low) was determined by follow-up to assess metabolic response of the pre and post treatment GATATE-FDG PET-CT results.
Significant correlation were noted in the Ki-67 (mean: 6.16± 8.21 %) and the FDG SUVmax (mean: 5.72±5.24;g/dl p < 0.01) and inversely correlated with the Ga SUVmax (mean: 15.80 ±10.57g/dl; p< 0.05). Management impact in 12/21 patients was high (partial metabolic response or no recurrence) in 75% and low in 25% (progressive metabolic disease). The combined ki-67-GaTATE marker had independent predictive significance for management impact (likelihood ratio test for the whole model, p=0.008).
Dual-tracer assessment of FDG-GaTate PET-CT provide a valuable information on the NETs’ cellular differentiation. Combination of ki-67-GaTATE may potentially be used as a reliable predictive marker for the NETs’ management impact.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.